MX2011012027A - Espironucleosidos uracilicos oxetanicos. - Google Patents

Espironucleosidos uracilicos oxetanicos.

Info

Publication number
MX2011012027A
MX2011012027A MX2011012027A MX2011012027A MX2011012027A MX 2011012027 A MX2011012027 A MX 2011012027A MX 2011012027 A MX2011012027 A MX 2011012027A MX 2011012027 A MX2011012027 A MX 2011012027A MX 2011012027 A MX2011012027 A MX 2011012027A
Authority
MX
Mexico
Prior art keywords
sub
sup
phenyl
alkyl
optionally substituted
Prior art date
Application number
MX2011012027A
Other languages
English (en)
Inventor
Abdellah Tahri
Pierre Jean-Marie Bernard Raboisson
Lili Hu
Tim Hugo Maria Jonckers
Koen Vandyck
Steven Maurice Paula Van Hoof
Original Assignee
Janssen Products Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Products Lp filed Critical Janssen Products Lp
Publication of MX2011012027A publication Critical patent/MX2011012027A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/503—Pyridazines; Hydrogenated pyridazines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Compuestos de la fórmula I: (ver fórmula (I)) incluyendo cualquier estereoisómero posible de los mismos, en donde: R4 es un éster monofosfato, difosfato o trifosfato; o R4 es (ver fórmulas) R7 es fenilo opcionalmente sustituido, naftilo opcionalmente sustituido, o indolilo opcionalmente sustituido; R8 y R8' son hidrógeno, alquilo C1-C6, bencilo, o fenilo; o R8 y R8' forman cicloalquilo C3-C7; R9 es alquilo C1-C10, cicloalquilo C3-C7, fenilo o fenil-alquilo C1-C6, en donde la porción fenilo en el fenilo o en el fenil-alquilo C1-C6 está opcionalmente sustituida; o una sal o un solvato farmacéuticamente aceptable de los mismos; formulaciones farmacéuticas y el uso de los compuestos I como inhibidores del VHC.
MX2011012027A 2009-05-14 2010-05-11 Espironucleosidos uracilicos oxetanicos. MX2011012027A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09160215 2009-05-14
PCT/EP2010/056438 WO2010130726A1 (en) 2009-05-14 2010-05-11 Uracyl spirooxetane nucleosides

Publications (1)

Publication Number Publication Date
MX2011012027A true MX2011012027A (es) 2012-02-28

Family

ID=40823307

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012027A MX2011012027A (es) 2009-05-14 2010-05-11 Espironucleosidos uracilicos oxetanicos.

Country Status (39)

Country Link
US (2) US8481510B2 (es)
EP (2) EP2511282B1 (es)
JP (2) JP5778135B2 (es)
KR (1) KR101806837B1 (es)
CN (1) CN102439024B (es)
AP (1) AP2783A (es)
AR (1) AR076579A1 (es)
AU (1) AU2010247439B2 (es)
BR (1) BRPI1010579A2 (es)
CA (1) CA2760329C (es)
CL (1) CL2011002859A1 (es)
CO (1) CO6440533A2 (es)
CR (1) CR20120297A (es)
CY (2) CY1114081T1 (es)
DK (2) DK2430035T3 (es)
EA (1) EA022084B1 (es)
EC (1) ECSP11011461A (es)
ES (2) ES2477598T3 (es)
HK (1) HK1166326A1 (es)
HN (1) HN2011003014A (es)
HR (2) HRP20130554T1 (es)
IL (1) IL215955A (es)
JO (1) JO3027B1 (es)
ME (1) ME01478B (es)
MX (1) MX2011012027A (es)
MY (1) MY157018A (es)
NI (1) NI201100197A (es)
NZ (1) NZ596073A (es)
PL (2) PL2511282T3 (es)
PT (2) PT2511282E (es)
RS (1) RS52822B (es)
SG (1) SG175981A1 (es)
SI (2) SI2430035T1 (es)
SM (2) SMT201300078B (es)
TW (1) TWI461432B (es)
UA (1) UA105790C2 (es)
UY (1) UY32642A (es)
WO (1) WO2010130726A1 (es)
ZA (1) ZA201108309B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
JO3027B1 (ar) * 2009-05-14 2016-09-05 Janssen Products Lp نيوكليوسيدات يوراسيل سبيرواوكسيتان
EP2638054B1 (en) * 2010-11-10 2014-12-03 Janssen Products, L.P. Uracyl spirooxetane nucleoside phosphoramidates
ES2605433T3 (es) * 2010-11-10 2017-03-14 Janssen Products, L.P. Fosforamidatos de espironucleósido oxetánico uracílico
AR084044A1 (es) * 2010-11-30 2013-04-17 Pharmasset Inc Compuestos 2’-espiro-nucleosidos
AU2015252113B2 (en) * 2010-11-30 2017-05-04 Gilead Pharmasset Llc Compounds
US8877733B2 (en) * 2011-04-13 2014-11-04 Gilead Sciences, Inc. 1′-substituted pyrimidine N-nucleoside analogs for antiviral treatment
EP2794630A4 (en) * 2011-12-22 2015-04-01 Alios Biopharma Inc SUBSTITUTED PHOSPHORTHIOAT NUCLEOTIDE ANALOGUE
UY34824A (es) * 2012-05-25 2013-11-29 Janssen R & D Ireland Nucleósidos de espirooxetano de uracilo
CA2899763C (en) 2013-03-08 2020-03-10 Nanjing Sanhome Pharmaceutical Co., Ltd. Nucleoside phosphoramidate compound and use thereof
CN105377868A (zh) 2013-04-12 2016-03-02 艾其林医药公司 用于治疗hcv的高活性核苷衍生物
CN104231023B (zh) * 2013-06-06 2019-02-05 南京汇诚制药有限公司 三环稠杂环类核苷氨基磷酸酯化合物、其制备方法及应用
EP3074412A4 (en) * 2013-11-28 2017-05-31 Janssen Sciences Ireland UC Crystal form of nucleoside inhibitor of hcv
MY190867A (en) 2015-03-06 2022-05-13 Atea Pharmaceuticals Inc ? -d-2'-deoxy-2'-?-fluoro-2'- ? -c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
EA037868B1 (ru) 2016-09-07 2021-05-28 Атеа Фармасьютикалс, Инк. 2'-замещенные-n6-замещенные пуриновые нуклеотиды для лечения вызванных рнк-вирусом заболеваний
JP7066728B2 (ja) 2017-02-01 2022-05-13 アテア ファーマシューティカルズ， インコーポレイテッド Ｃ型肝炎ウイルスの治療のためのヌクレオチドヘミ硫酸塩
CN112351799A (zh) 2018-04-10 2021-02-09 阿堤亚制药公司 具有硬化的hcv感染患者的治疗
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
JP2023522612A (ja) * 2020-04-14 2023-05-31 ヤンセン ファーマシューティカルズ，インコーポレーテッド Ｅ型肝炎の治療のためのスピロ環式ヌクレオシド類似体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03006514A (es) * 2001-01-22 2004-12-02 Merck & Co Inc Derivados de nucleosidos como inhibidores de polimerasa de acido ribonucleico viral dependiente de acido ribonucleico.
US20070265222A1 (en) 2004-06-24 2007-11-15 Maccoss Malcolm Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection
CN101287472B (zh) * 2005-08-15 2011-10-12 弗·哈夫曼-拉罗切有限公司 抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物
WO2007095269A2 (en) * 2006-02-14 2007-08-23 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
PA8852101A1 (es) * 2008-12-08 2010-07-27 Medivir Ab Nucleótidos uracil ciclopropílicos
JO3027B1 (ar) * 2009-05-14 2016-09-05 Janssen Products Lp نيوكليوسيدات يوراسيل سبيرواوكسيتان

Also Published As

Publication number Publication date
DK2430035T3 (da) 2013-05-27
HRP20140605T1 (hr) 2014-09-26
US20120065156A1 (en) 2012-03-15
EP2511282A1 (en) 2012-10-17
JP2015180692A (ja) 2015-10-15
IL215955A0 (en) 2012-01-31
NZ596073A (en) 2013-02-22
AP2783A (en) 2013-10-31
CR20120297A (es) 2012-10-25
SMT201400085B (it) 2014-09-08
RS52822B (en) 2013-10-31
US20130217648A1 (en) 2013-08-22
AP2011005958A0 (en) 2011-10-31
SG175981A1 (en) 2011-12-29
CN102439024B (zh) 2014-09-17
CO6440533A2 (es) 2012-05-15
ES2477598T3 (es) 2014-07-17
CA2760329C (en) 2017-10-31
ZA201108309B (en) 2013-04-24
ECSP11011461A (es) 2012-02-29
PT2430035E (pt) 2013-05-22
AR076579A1 (es) 2011-06-22
PT2511282E (pt) 2014-07-11
DK2511282T3 (da) 2014-07-07
SMT201300078B (it) 2013-09-06
TW201100442A (en) 2011-01-01
HK1166326A1 (en) 2012-10-26
EA201171406A1 (ru) 2012-05-30
ME01478B (me) 2014-04-20
PL2430035T3 (pl) 2013-08-30
US8481510B2 (en) 2013-07-09
CL2011002859A1 (es) 2012-07-20
IL215955A (en) 2015-03-31
PL2511282T3 (pl) 2014-09-30
AU2010247439B2 (en) 2014-09-25
CN102439024A (zh) 2012-05-02
BRPI1010579A2 (pt) 2016-03-15
KR20120018355A (ko) 2012-03-02
HN2011003014A (es) 2014-06-30
UA105790C2 (uk) 2014-06-25
SI2430035T1 (sl) 2013-08-30
US8933052B2 (en) 2015-01-13
EP2430035B1 (en) 2013-04-03
JP2012526764A (ja) 2012-11-01
WO2010130726A1 (en) 2010-11-18
EA022084B1 (ru) 2015-10-30
ES2411086T3 (es) 2013-07-04
TWI461432B (zh) 2014-11-21
EP2511282B1 (en) 2014-04-02
JP5778135B2 (ja) 2015-09-16
UY32642A (es) 2010-11-30
CY1114081T1 (el) 2016-07-27
HRP20130554T1 (en) 2013-07-31
AU2010247439A1 (en) 2011-12-01
CY1115383T1 (el) 2017-01-04
KR101806837B1 (ko) 2017-12-08
JO3027B1 (ar) 2016-09-05
EP2430035A1 (en) 2012-03-21
NI201100197A (es) 2012-05-28
SI2511282T1 (sl) 2014-09-30
CA2760329A1 (en) 2010-11-18
MY157018A (en) 2016-04-15

Similar Documents

Publication Publication Date Title
MX2011012027A (es) Espironucleosidos uracilicos oxetanicos.
UY32308A (es) Nucleótidos uracil ciclopropílicos
CO6331437A2 (es) Compuestos de pirrolo[2,3-d]pirimidina
CO6321255A2 (es) "inhibidores de ciclopropil polimerasa"
WO2011039221A3 (en) Phosphoramidate derivatives of nucleosides
PH12014502771A1 (en) Nucleoside phosphoramidate prodrugs
MX2009008540A (es) Inhibidores de virus de hepatitis c macrociclicos sustituidos con pirimidina.
CR8756A (es) Derivados de acido carboxilico bencimidazolona
NZ553405A (en) Nucleoside phosphonate conjugates as anti-HIV agents
AR062745A1 (es) 2-[4-(7-etil-5h-pirrolo[2,3-b]pirazin-6-il)-fenil]-propan-2-ol como inhibidor de quinasa
JO2643B1 (en) Derivatives of 2-aryl-6-phenylimidazole [a-1,2] pyridine, their preparation and therapeutic use
MX2011011136A (es) Eteres diarilicos.
ECSP109932A (es) Compuestos de biciclolactama sustituida
PH12014501283A1 (en) 4`-azido, 3``-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication
NO20090835L (no) Nye HIV-reverstranskriptaseinhibitorer
MX2009013804A (es) Inhibidores novedosos de transcriptasa inversa de vih.
JO3577B1 (ar) صيغ صيدلانية تشمل مشتقات 1-(بيتا-d- غلوكوبيرانوسيل) -2-ثينيل ميثيل بنزين كمثبطات sglt
MX2012004089A (es) Inhibidores de hsp90.
WO2008011117A3 (en) Antiviral protease inhibitors
NZ592314A (en) Sulfoximine-substituted anilinopyrimidine derivatives as cdk inhibitors, the production thereof, and use as medicine
PE20060478A1 (es) Acidos 4-trifluorometoxifenoxibenceno-4'-sulfonicos y procedimientos para su preparacion
TH112183B (th) สารยับยั้งไซโคลโพรพิล พอลิเมอเรส
TH112183A (th) สารยับยั้งไซโคลโพรพิล พอลิเมอเรส
MY183638A (en) Nucleoside phosphoramidate prodrugs
TH124818B (th) นิวคลิโอไซด์ และ นิวคลิโอไทด์แอนะล็อก ที่ถูกแทนที่

Legal Events

Date Code Title Description
FG Grant or registration